Venous Thromboembolism in Japanese Patients With Pancreatic Cancer

Objective Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in Japan. Previous studies from other countries have reported venous thromboembolism prevalence rates of 12 to 36% in patients with pancreatic cancer. In this study, we aimed to determine the incid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takahito Suzuki MD, Reina Hori MD, Kazutaka Takeuchi MD, Ryo Yamamura MD, Hiromasa Katoh MD, Yoshihiro Noji MD, Masato Yamaguchi MD, Susumu Fujino MD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/25f8261e73cf4b9ab093108c4deb20b8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:25f8261e73cf4b9ab093108c4deb20b8
record_format	dspace
spelling	oai:doaj.org-article:25f8261e73cf4b9ab093108c4deb20b82021-11-03T23:03:23ZVenous Thromboembolism in Japanese Patients With Pancreatic Cancer1938-272310.1177/10760296211051766https://doaj.org/article/25f8261e73cf4b9ab093108c4deb20b82021-11-01T00:00:00Zhttps://doi.org/10.1177/10760296211051766https://doaj.org/toc/1938-2723Objective Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in Japan. Previous studies from other countries have reported venous thromboembolism prevalence rates of 12 to 36% in patients with pancreatic cancer. In this study, we aimed to determine the incidence of VTE in patients with PDAC in Japan and compare the characteristics of patients with and without VTE. Methods In this retrospective cohort study, clinicopathological characteristics of patients with and without concomitant VTE were compared. Patients Patients with PDAC treated at Fukui Prefectural Hospital, Japan from 2010 to 2019. Results The 1-year survival rate of all patients with pancreatic cancer was 40.7%. Among 432 patients with PDAC, 31 developed VTE. Seventeen (55%) patients received anticoagulant therapy. Compared with the non-VTE group, the VTE group had significantly more patients whose body mass index was >25 kg/m² ( p = .035) and had a significantly higher rate of chemotherapy ( p = .024). There was no significant difference in median survival time from PDAC diagnosis between the VTE and non-VTE groups. The 6-month mortality rate after VTE diagnosis was 54.8%. PDAC-related death was the most frequent cause of death, and thrombus-related death was not observed. Conclusion Several baseline characteristics differed between patients with and without VTE. The incidence of VTE in patients with PDAC is high. However, because the prognosis of PDAC itself remains quite poor, VTE may not have a significant effect on prognosis.Takahito Suzuki MDReina Hori MDKazutaka Takeuchi MDRyo Yamamura MDHiromasa Katoh MDYoshihiro Noji MDMasato Yamaguchi MDSusumu Fujino MDSAGE PublishingarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENClinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Takahito Suzuki MD Reina Hori MD Kazutaka Takeuchi MD Ryo Yamamura MD Hiromasa Katoh MD Yoshihiro Noji MD Masato Yamaguchi MD Susumu Fujino MD Venous Thromboembolism in Japanese Patients With Pancreatic Cancer
description	Objective Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in Japan. Previous studies from other countries have reported venous thromboembolism prevalence rates of 12 to 36% in patients with pancreatic cancer. In this study, we aimed to determine the incidence of VTE in patients with PDAC in Japan and compare the characteristics of patients with and without VTE. Methods In this retrospective cohort study, clinicopathological characteristics of patients with and without concomitant VTE were compared. Patients Patients with PDAC treated at Fukui Prefectural Hospital, Japan from 2010 to 2019. Results The 1-year survival rate of all patients with pancreatic cancer was 40.7%. Among 432 patients with PDAC, 31 developed VTE. Seventeen (55%) patients received anticoagulant therapy. Compared with the non-VTE group, the VTE group had significantly more patients whose body mass index was >25 kg/m² ( p = .035) and had a significantly higher rate of chemotherapy ( p = .024). There was no significant difference in median survival time from PDAC diagnosis between the VTE and non-VTE groups. The 6-month mortality rate after VTE diagnosis was 54.8%. PDAC-related death was the most frequent cause of death, and thrombus-related death was not observed. Conclusion Several baseline characteristics differed between patients with and without VTE. The incidence of VTE in patients with PDAC is high. However, because the prognosis of PDAC itself remains quite poor, VTE may not have a significant effect on prognosis.
format	article
author	Takahito Suzuki MD Reina Hori MD Kazutaka Takeuchi MD Ryo Yamamura MD Hiromasa Katoh MD Yoshihiro Noji MD Masato Yamaguchi MD Susumu Fujino MD
author_facet	Takahito Suzuki MD Reina Hori MD Kazutaka Takeuchi MD Ryo Yamamura MD Hiromasa Katoh MD Yoshihiro Noji MD Masato Yamaguchi MD Susumu Fujino MD
author_sort	Takahito Suzuki MD
title	Venous Thromboembolism in Japanese Patients With Pancreatic Cancer
title_short	Venous Thromboembolism in Japanese Patients With Pancreatic Cancer
title_full	Venous Thromboembolism in Japanese Patients With Pancreatic Cancer
title_fullStr	Venous Thromboembolism in Japanese Patients With Pancreatic Cancer
title_full_unstemmed	Venous Thromboembolism in Japanese Patients With Pancreatic Cancer
title_sort	venous thromboembolism in japanese patients with pancreatic cancer
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/25f8261e73cf4b9ab093108c4deb20b8
work_keys_str_mv	AT takahitosuzukimd venousthromboembolisminjapanesepatientswithpancreaticcancer AT reinahorimd venousthromboembolisminjapanesepatientswithpancreaticcancer AT kazutakatakeuchimd venousthromboembolisminjapanesepatientswithpancreaticcancer AT ryoyamamuramd venousthromboembolisminjapanesepatientswithpancreaticcancer AT hiromasakatohmd venousthromboembolisminjapanesepatientswithpancreaticcancer AT yoshihironojimd venousthromboembolisminjapanesepatientswithpancreaticcancer AT masatoyamaguchimd venousthromboembolisminjapanesepatientswithpancreaticcancer AT susumufujinomd venousthromboembolisminjapanesepatientswithpancreaticcancer
_version_	1718445319339900928

Venous Thromboembolism in Japanese Patients With Pancreatic Cancer

Ejemplares similares